AIM: To evaluate risk factors related to total mortality in an unselected population of patients implanted with a cardioverter defibrillator. METHODS: Survival analysis was performed retrospectively investigating the records of 77 consecutive patients implanted with defibrillators (median 67 years, range 38-83 years; 63 men). All patients were followed regularly in 3-month intervals. The cause of mortality was assessed clinically, including post-mortem examination of device to assess possible arrhythmogenic death. Predictors were assessed by Kaplan-Meier analysis with log-rank tests and by Cox regression analysis (proportional hazards). RESULTS: Defibrillator recipients had a mean (+/-standard deviation) ejection fraction of 34+/-13%, left ventricular end-diastolic dimension (LVEDD) of 6.24+/-0.8 cm, QRS duration of 129+/-34 ms, and body mass index (BMI) of 26.4+/-4.3 kg/m(2). Atrial fibrillation was present in 32 patients, paroxysmal fibrillation in 23, and permanent fibrillation in 9 patients. The estimate of mean survival time for all patients was 51.5 (95% confidence interval 46.6-56.5) months. During the study period 11/77 (14%) patients died. Mean follow-up time was 24.5 months (range 0.2-60.7) for survivors and 7.6 months (range 1.5-42) for non-survivors. Independent predictors of mortality were the NYHA class (P=0.004), BMI< or =26 kg/m(2) (P=0.024), presence of paroxysmal or permanent atrial fibrillation (P=0.014), and absence of arterial hypertension (P=0.010). LVEDD showed a weak significant effect on survival (P=0.049). CONCLUSION: Patients with implantable cardioverter defibrillator and a normal to lower BMI or atrial fibrillation had a significantly higher overall mortality. These factors may be indicative of end stage heart failure or diseases associated with high sympathetic activation.
AIM: To evaluate risk factors related to total mortality in an unselected population of patients implanted with a cardioverter defibrillator. METHODS: Survival analysis was performed retrospectively investigating the records of 77 consecutive patients implanted with defibrillators (median 67 years, range 38-83 years; 63 men). All patients were followed regularly in 3-month intervals. The cause of mortality was assessed clinically, including post-mortem examination of device to assess possible arrhythmogenic death. Predictors were assessed by Kaplan-Meier analysis with log-rank tests and by Cox regression analysis (proportional hazards). RESULTS: Defibrillator recipients had a mean (+/-standard deviation) ejection fraction of 34+/-13%, left ventricular end-diastolic dimension (LVEDD) of 6.24+/-0.8 cm, QRS duration of 129+/-34 ms, and body mass index (BMI) of 26.4+/-4.3 kg/m(2). Atrial fibrillation was present in 32 patients, paroxysmal fibrillation in 23, and permanent fibrillation in 9 patients. The estimate of mean survival time for all patients was 51.5 (95% confidence interval 46.6-56.5) months. During the study period 11/77 (14%) patients died. Mean follow-up time was 24.5 months (range 0.2-60.7) for survivors and 7.6 months (range 1.5-42) for non-survivors. Independent predictors of mortality were the NYHA class (P=0.004), BMI< or =26 kg/m(2) (P=0.024), presence of paroxysmal or permanent atrial fibrillation (P=0.014), and absence of arterial hypertension (P=0.010). LVEDD showed a weak significant effect on survival (P=0.049). CONCLUSION:Patients with implantable cardioverter defibrillator and a normal to lower BMI or atrial fibrillation had a significantly higher overall mortality. These factors may be indicative of end stage heart failure or diseases associated with high sympathetic activation.
Authors: Stefan H Hohnloser; Karl Heinz Kuck; Paul Dorian; Robin S Roberts; John R Hampton; Robert Hatala; Eric Fain; Michael Gent; Stuart J Connolly Journal: N Engl J Med Date: 2004-12-09 Impact factor: 91.245
Authors: Jagmeet P Singh; W Jackson Hall; Scott McNitt; Hongyue Wang; James P Daubert; Wojciech Zareba; Jeremy N Ruskin; Arthur J Moss Journal: J Am Coll Cardiol Date: 2005-10-10 Impact factor: 24.094
Authors: Gust H Bardy; Kerry L Lee; Daniel B Mark; Jeanne E Poole; Douglas L Packer; Robin Boineau; Michael Domanski; Charles Troutman; Jill Anderson; George Johnson; Steven E McNulty; Nancy Clapp-Channing; Linda D Davidson-Ray; Elizabeth S Fraulo; Daniel P Fishbein; Richard M Luceri; John H Ip Journal: N Engl J Med Date: 2005-01-20 Impact factor: 91.245
Authors: Anant K Vyas; Hongsheng Guo; Arthur J Moss; Brian Olshansky; Scott A McNitt; W Jackson Hall; Wojciech Zareba; Jonathan S Steinberg; Avi Fischer; Jeremy Ruskin; Mark L Andrews Journal: J Am Coll Cardiol Date: 2006-01-30 Impact factor: 24.094